Frailty and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. This is an ASCO Meeting Abstract from the 2023 ASCO Genitourinary Cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results